Literature DB >> 20145258

Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period.

Anne Sophie Benichou1, Benoit Blanchet, Filomena Conti, Maryline Hornecker, Denis Bernard, Fabrice Taieb, Olivier Scatton, Halim Abbas, Laura Harcouet, Alain Dauphin, Yvon Calmus, Michel Tod.   

Abstract

Mycophenolate mofetil (MMF) pharmacokinetics variability in liver transplant recipients during the early posttransplantation period may be related to changes in mycophenolic acid (MPA) protein binding. This study aimed at characterizing the variation of free MPA exposure with respect to time since transplantation. Three groups (A, B, C) were compared. The median posttransplantation time was 12 days (A, n = 26 pharmacokinetic sessions), 36 days (B, n = 25), and 867 days (C, n = 21). The median MPA AUC(0-12) in group A (26.8 mg x h/L) was significantly lower than in groups B (45.2 mg x h/L, P = .031) and C (43.5 mg x h/L, P = .004). Free MPA AUC(0-12) was comparable whatever the time (0.41, 0.34, and 0.33 mg x h/L, respectively). MPA apparent clearance (CL/F) was significantly correlated with MPA free fraction (r = 0.60, P < .0001) and approximately 1.7-fold higher in group A compared to groups B and C (P < .05). Enhanced CL/F in relation with an increase in MPA free fraction results in a low AUC of total MPA during the first postoperative month, but on average, at the population level, the exposure to free MPA is not altered, suggesting that total MPA AUC should not be used to adapt MMF dosing during this period.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145258     DOI: 10.1177/0091270009358084

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Calculation of normalized drug concentrations in the presence of altered plasma protein binding.

Authors:  Florin Marcel Musteata
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

Review 2.  Clinical mycophenolic acid monitoring in liver transplant recipients.

Authors:  Hao Chen; Bing Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.

Authors:  Michel Tod; Olivier Mir; Natacha Bancelin; Romain Coriat; Audrey Thomas-Schoemann; Fabrice Taieb; Pascaline Boudou-Rouquette; Stanislas Ropert; Judith Michels; Halim Abbas; Jean Philippe Durand; Alain Dauphin; Michel Vidal; Francois Goldwasser; Benoit Blanchet
Journal:  Pharm Res       Date:  2011-06-21       Impact factor: 4.200

4.  Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.

Authors:  Caroline Barau; Valérie Furlan; Dominique Debray; Anne-Marie Taburet; Aurélie Barrail-Tran
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

5.  Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach.

Authors:  Helena Colom; Franc Andreu; Teun van Gelder; Dennis A Hesselink; Brenda C M de Winter; Oriol Bestard; Joan Torras; Josep M Cruzado; Josep M Grinyó; Núria Lloberas
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.